Idorsia provides update on the exclusive negotiations for the global rights to aprocitentan
December 20, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Company announces delay to the targeted timeline for signing a binding agreementCompany in discussions with bondholders to restructure the company’s...
Idorsia enters into exclusive negotiations for global rights to aprocitentan
November 27, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Company enters into exclusive negotiations with an undisclosed party for global rights to aprocitentanCompany to streamline the business, resulting in cost...
Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions
November 11, 2024 11:45 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – November 11, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, the first-and-only dual endothelin receptor antagonist (ERA) for the treatment of...
Idorsia announces financial results for the first nine months of 2024
October 29, 2024 02:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 29, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2024. Highlights Net...
New data on aprocitentan to be presented at the ASN Kidney Week 2024
October 16, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – October 16, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented at the American Society of...
Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024
September 17, 2024 11:45 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – September 17, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data and analyses of daridorexant, Idorsia’s dual orexin receptor antagonist for the treatment of adults...
New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024
September 05, 2024 11:45 ET
|
Idorsia Pharmaceuticals Ltd
Two abstracts win the prestigious AHA 2024 Paul Dudley White International Scholar Award Allschwil, Switzerland – September 5, 2024Idorsia Ltd (SIX: IDIA) today announced that new data on...
Amended terms of Idorsia’s 2024 convertible bonds become effective
September 02, 2024 11:45 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – September 2, 2024 Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period – during which no appeal...
Idorsia announces financial results for the first half 2024
July 25, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2024. Business highlights ...
Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension
July 01, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Idorsia receives approval from the European Commission (EC) for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.JERAYGO...